Alnylam Pharmaceuticals (ALNY) Other Non-Current Liabilities (2009 - 2026)

Alnylam Pharmaceuticals' Other Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $7.6 million for Q1 2026.

• Quarterly Other Non-Current Liabilities rose 29.64% year-over-year to $7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.6 million (up 29.64% YoY) and the FY2025 annual result came in at $7.6 million, down 98.44% from the prior year.
• Other Non-Current Liabilities was $7.6 million for Q1 2026 at Alnylam Pharmaceuticals, roughly flat from $7.6 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $486.9 million in Q4 2024 and bottomed at $5.9 million in Q1 2025.
• A 5-year average of $194.2 million and a median of $212.6 million in 2022 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities surged 139.37% — and 2025, when it sank 98.44%.
• Alnylam Pharmaceuticals' Other Non-Current Liabilities stood at $212.6 million in 2022, then surged by 45.09% to $308.4 million in 2023, then soared by 57.87% to $486.9 million in 2024, then sank by 98.44% to $7.6 million in 2025, then increased by 0.22% to $7.6 million in 2026.
• Business Quant data shows ALNY's Other Non-Current Liabilities at $7.6 million in Q1 2026, $7.6 million in Q4 2025, and $9.8 million in Q3 2025.